Anal Cancer

What Is Anal Cancer?

Anal cancer develops at the junction where the rectum meets the anus. Most are squamous cell carcinomas. The disease is highly associated with HPV infection (similar to cervical cancer).

Key fact: Unlike colorectal cancer, chemoradiation (not surgery) is the primary treatment, allowing preservation of normal sphincter function and continence in most patients.

Risk Factors

• HPV infection: Most important risk factor. HPV-16 and HPV-18 strongly associated. Vaccination prevents anal cancer.
• Receptive anal intercourse: Increases HPV transmission risk.
• Immunosuppression: HIV+ individuals have higher risk, especially with low CD4 counts.
• History of cervical or vulvar cancer: In women with HPV-related cancers, anal cancer risk increased.
• Smoking: Increases risk and may worsen chemoradiation toxicity.

Symptoms

• Rectal bleeding or bloody stools
• Anal pain or pressure
• Anal mass or lump (noted by patient)
• Anal itching
• Change in bowel habits
• Enlarged lymph nodes in groin or abdomen

Important: Many patients with anal symptoms avoid seeking care due to embarrassment. Any persistent anal symptoms warrant medical evaluation.

Diagnosis

Diagnostic approach:

• Digital rectal exam (DRE): First step; palpates for mass.
• Anoscopy: Direct visualization with biopsy for pathologic confirmation.
• HPV testing: Identifies HPV status; prognostic value.
• Staging imaging: CT or MRI pelvis (local extent), CT chest (distant metastases).
• PET scan: May help identify metastatic disease.

Staging

Uses TNM system. Tumors are typically classified by:

• T: Tumor size and extent (T1: <2cm, T2: 2-5cm, T3: >5cm, T4: invasion of adjacent structures)
• N: Lymph node involvement (N0, N1, N2, N3 based on location and number)
• M: Distant metastases (M0 vs M1)

Treatment Options

Chemoradiation (Standard Treatment)

Nigro protocol (named after its developer) is the gold standard:

• Chemotherapy: Mitomycin C (single dose week 1) + 5-FU (continuous infusion for 4-5 weeks)
• Radiation: 45-54 Gy external beam radiation over 5-6 weeks to primary tumor and regional nodes

Cure rates: 80-90% for localized disease without surgery.

Surgery

Reserved for:

• Residual disease after chemoradiation (salvage abdominoperineal resection/APR)
• Recurrent disease
• Poor performance status unable to tolerate chemoradiation

APR involves removal of rectum and anus with permanent colostomy.

Surveillance After Chemoradiation

Most patients achieve complete response and are cured. Surveillance includes clinical exam, imaging, and assessment for late toxicity.

Side Effects & Toxicity

Acute side effects (during chemoradiation):

• Severe dermatitis (skin irritation in irradiated area)
• Diarrhea and proctitis (inflammation of rectum)
• Anal pain
• Nausea and myelosuppression (from chemotherapy)

Late side effects (months to years after):

• Chronic diarrhea or constipation
• Fecal incontinence (usually minor)
• Sexual dysfunction
• Stenosis (narrowing) of anus or rectum (rare)

Management: Most side effects managed supportively. Smoking cessation improves outcomes and reduces toxicity.

Prognosis

Excellent with chemoradiation:

• Early-stage (T1-2, N0): 80-90% 5-year survival.
• Locally advanced (T3-4 or N+): 60-75% 5-year survival.
• Metastatic: Palliative chemotherapy; median survival 12-18 months.

HPV status may affect prognosis, with HPV-positive disease potentially having better outcomes.

Key Questions for Your Doctor

• What is my stage?
• What is my HPV status?
• Am I a candidate for standard chemoradiation?
• What are specific side effects I should expect?
• How is response to treatment monitored?
• What happens if there is residual disease after chemoradiation?
• Are there clinical trials for anal cancer?